TY  - JOUR
AU  - Bacsur, Péter
AU  - Resál, Tamás
AU  - Farkas, Bernadett
AU  - Sarlós, P
AU  - Iliás, Á
AU  - Kata, Diána
AU  - Bálint, Anita
AU  - Fábián, Anna
AU  - Bor, Renáta
AU  - Szepes, Zoltán
AU  - Molnár, Tamás
AU  - Farkas, Klaudia
TI  - P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment
JF  - JOURNAL OF CROHNS & COLITIS
J2  - J CROHNS COLITIS
VL  - 18
PY  - 2024
IS  - Supplement_1
SP  - i1279
EP  - i1280
PG  - 2
SN  - 1873-9946
DO  - 10.1093/ecco-jcc/jjad212.0804
UR  - https://m2.mtmt.hu/api/publication/34538619
ID  - 34538619
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Pallagi, Petra
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - P421 The faecal biomarker LDN-051 is a novel tool for monitoring disease activity and therapeutic response in Inflammatory Bowel Diseases
JF  - JOURNAL OF CROHNS & COLITIS
J2  - J CROHNS COLITIS
VL  - 18
PY  - 2024
IS  - Supplement_1
SP  - i869
EP  - i869
PG  - 1
SN  - 1873-9946
DO  - 10.1093/ecco-jcc/jjad212.0551
UR  - https://m2.mtmt.hu/api/publication/34538603
ID  - 34538603
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Pallagi, Petra
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases
JF  - JOURNAL OF CROHNS & COLITIS
J2  - J CROHNS COLITIS
VL  - 18
PY  - 2024
IS  - 3
SP  - 392
EP  - 405
PG  - 14
SN  - 1873-9946
DO  - 10.1093/ecco-jcc/jjad160
UR  - https://m2.mtmt.hu/api/publication/34167015
ID  - 34167015
N1  - Ladon Therapeutics Ltd, Szeged, Hungary            
            Department of Medicine, University of Szeged, Szeged, Hungary            
            ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged, Szeged, Hungary            
            HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged, Szeged, Hungary            
            Faculty of Medicine, Institute of Laboratory Medicine, University of Szeged, Szeged, Hungary            
            Export Date: 8 April 2024            
            Correspondence Address: Maléth, J.; HAS-USZ Momentum Epithelial Cell Signalling and Secretion Research Group, Hungary; email: maleth.jozsef@med.uszeged.hu            
            Correspondence Address: Farkas, K.; HAS-USZ Momentum Epithelial Cell Signalling and Secretion Research Group, Hungary            
            Chemicals/CAS: adalimumab, 331731-18-1, 1446410-95-2; azathioprine, 446-86-6, 55774-33-9; budesonide, 51333-22-3, 51372-29-3; cyclosporine, 59865-13-3, 63798-73-2, 79217-60-0; infliximab, 170277-31-3; mesalazine, 89-57-6; plasminogen activator inhibitor 1, 140208-23-7; tofacitinib, 477600-75-2, 540737-29-9; ustekinumab, 815610-63-0, 949907-93-1; vedolizumab, 943609-66-3; Biomarkers; Plasminogen Activator Inhibitor 1            
            Tradenames: 201170, Greiner; ab269373, Abcam; ChemiDoc MP, Biorad; GraphPad 9.5.0, Graphpad; iScript cDNA Synthesis Kit, Biorad; MedCalc Software 20.211, MedCalc; Multiskan FC, Thermo; NucleoSpin RNA Plus Kit, Macherey            
            Manufacturers: Abcam; Biorad; Carl Zeiss; Graphpad; Greiner; Macherey; MedCalc; Thermo
AB  - Crohn's disease and ulcerative colitis require lifelong treatment and patient monitoring. Current biomarkers have several limitations, therefore, there is an unmet need to identify novel biomarkers in inflammatory bowel disease (IBD). Previously, the role of plasminogen activator inhibitor 1 (PAI-1) was established in the pathogenesis of IBD and suggested as a potential biomarker. Therefore, we aimed to comprehensively analyze the selectivity of PAI-1 in IBD, its correlation with the disease activity, and its potential to predict therapeutic response.Blood, colon biopsy, organoid cultures (OC), and faecal samples were used from active and inactive IBD patients and control subjects. Serpin E1 gene expressions and PAI-1 protein levels and localization in serum, biopsy, and fecal samples were evaluated by qRT-PCR, ELISA, and immunostaining, respectively.The study population comprised 132 IBD patients (56 CD and 76 UC) and 40 non-IBD patients. We demonstrated that the serum, mucosal, and faecal PAI-1 concentration is elevated in IBD patients, showing clinical and endoscopic activity. In responders (decrease of eMayo≥3 in UC; or SES-CD>50% in CD), the initial PAI-1 level decreased significantly upon successful therapy. OCs derived from active IBD patients produced higher concentrations of PAI-1 than the controls, suggesting that epithelial cells could be a source of PAI-1. Moreover, faecal PAI-1 selectively increases in active IBD but not other organic gastrointestinal diseases.The serum, mucosal, and faecal PAI-1 concentration correlates with the disease activity and therapeutic response in IBD, suggesting that PAI-1 could be utilized as a novel non-invasive, disease-specific faecal biomarker in the patient follow-up.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - LDN-051 a novel fecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases – results of a phase 2 clinical trial
JF  - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
J2  - UEG JOURNAL
VL  - 11
PY  - 2023
IS  - S8
SP  - 291
EP  - 292
PG  - 2
SN  - 2050-6406
UR  - https://m2.mtmt.hu/api/publication/34593890
ID  - 34593890
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bacsur, Péter
AU  - Iliás, Ákos
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tamás
AU  - Farkas, Klaudia
TI  - Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary
JF  - ALIMENTARY PHARMACOLOGY & THERAPEUTICS
J2  - ALIMENT PHARM THER
VL  - 58
PY  - 2023
IS  - 2
SP  - 262
EP  - 263
PG  - 2
SN  - 0269-2813
DO  - 10.1111/apt.17610
UR  - https://m2.mtmt.hu/api/publication/34034445
ID  - 34034445
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - Plasminogen activator inhibitor 1 - a novel potential biomarker in inflammatory bowel diseases
JF  - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE
J2  - CENT EUR J GASTRO HEPATOL
VL  - 9
PY  - 2023
IS  - Suppl. 1
SP  - 85
EP  - 85
PG  - 1
SN  - 2415-9107
UR  - https://m2.mtmt.hu/api/publication/34012213
ID  - 34012213
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Molnár, Tünde
AU  - Kata, Diána
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Resál, Tamás
AU  - Bacsur, Péter
AU  - Szántó, Kata Judit
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - Identification of the PAI-1, as a potential non-invasive, fecal biomarker in the Inflammatory Bowel Diseases
JF  - JOURNAL OF CROHNS & COLITIS
J2  - J CROHNS COLITIS
VL  - 17
PY  - 2023
IS  - Supplement_1
SP  - i336
EP  - i337
SN  - 1873-9946
DO  - 10.1093/ecco-jcc/jjac190.0314
UR  - https://m2.mtmt.hu/api/publication/33611606
ID  - 33611606
LA  - English
DB  - MTMT
ER  - 

TY  - CONF
AU  - Molnár, Tünde
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Szántó, Kata Judit
AU  - Kata, Diána
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - Human colon organoids as disease model of inflammatory bowel disease
T2  - Abstracts of papers presented at the EMBL Partnership Conference
PB  - European Molecular Biology Laboratory (EMBL)
C1  - Heidelberg
PY  - 2022
SP  - 142
EP  - 142
PG  - 1
UR  - https://m2.mtmt.hu/api/publication/34014805
ID  - 34014805
LA  - English
DB  - MTMT
ER  - 

TY  - CONF
AU  - Jójárt, Boldizsár
AU  - Molnár, Tünde
AU  - Kata, Diána
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Resál, Tamás
AU  - Bacsur, Péter
AU  - Szántó, Kata Judit
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - PAI-1 level reflects to the disease activity and therapy response in inflammatory bowel disease - potential new biomarker
T2  - Abstracts of papers presented at the EMBL Partnership Conference
PB  - European Molecular Biology Laboratory (EMBL)
C1  - Heidelberg
PY  - 2022
SP  - 119
EP  - 119
PG  - 1
UR  - https://m2.mtmt.hu/api/publication/34014799
ID  - 34014799
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Molnár, Tünde
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Szántó, Kata Judit
AU  - Kata, Diána
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - Defining the human colon organoid’s cytokine pattern in inflammatory bowel disease
JF  - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE
J2  - CENT EUR J GASTRO HEPATOL
VL  - 8
PY  - 2022
IS  - Suppl. 1
SP  - 91
EP  - 91
PG  - 1
SN  - 2415-9107
UR  - https://m2.mtmt.hu/api/publication/34013131
ID  - 34013131
LA  - English
DB  - MTMT
ER  -